Skip to main content
. 2010 Feb 4;12(8):871–881. doi: 10.1093/neuonc/nop054

Fig. 2.

Fig. 2.

Kaplan–Meier estimate of overall survival for all efficacy evaluable (EE) patients. Treatment with IL13-PE38QQR: Total (censored) = 118 (28); Median (95% CI) = 45.3 (34.71–52.57). Treatment with Gliadel wafer: Total (censored) = 70 (16); Median (95% CI) = 39.8 (34.86–50.43). CB compared with Gliadel wafer hazard ratio (2-sided; 95% CI): 0.81 (0.58–1.14), P value = 0.234.